Topic: Dna Data

Google and Amazon have admitted they will provide surveillance footage from Ring and Nest doorbells to police without a warrant in certain circumstances. Additionally, concerns are raised about DNA data from 23andMe being accessible to Chinese interests for the development of "genetically targeted" bioweapons. The segment warns against the long-term privacy risks of voluntarily providing biometric and surveillance data to tech giants.

The End User License Agreement (EULA) for AncestryDNA is scrutinized for clauses that grant the company a perpetual, royalty-free, worldwide license to use a customer's DNA data. The discussion highlights that after three years, users may lose certain claims to the ownership of their test results while the company retains usage rights.

GlaxoSmithKline has invested $300 million in 23andMe to gain access to its database of 5 million customers for drug research. The hosts warn that DNA data is the ultimate personal information and express concern that these databases will inevitably be hacked or sold to "bad actors" in the pharmaceutical industry.

A security breach at the genealogy site MyHeritage exposed the email addresses of 92 million users. This news coincides with the implementation of the Rapid DNA Act of 2017, which allows law enforcement to match DNA samples to the FBI's CODIS database in minutes. The EFF has expressed concerns about the accuracy of these rapid tests, particularly in cases involving multiple DNA sources.

The hosts discuss the FDA's crackdown on 23andMe and the limitations of commercial DNA testing. Adam Curry advocates for using open-source tools like Promethease to analyze raw genetic data rather than trusting a Google-affiliated company with sensitive biological information.

The genetic testing company 23andMe, founded by Anne Wojcicki, is criticized as a "parlor trick" designed to collect massive amounts of DNA data. The hosts discuss an article about Sergey Brin's genetic predisposition for Parkinson's and argue that the company's true goal is "big data" monetization rather than personal health. They suggest that focusing on genetic flaws can lead to a self-fulfilling prophecy of illness.

The hosts discuss the history of Progressive Insurance, noting its origins as a data-driven company that used actuarial tables to predict driver risk. They argue that the insurance industry's ultimate goal is to acquire DNA data to perform advanced risk management, potentially denying coverage to individuals based on genetic predispositions to diseases. They warn that the "nothing to hide" argument regarding privacy fails to account for how personal data can be used for financial exclusion.